Information Provided By: 
Fly News Breaks for October 28, 2016
ADHD
Oct 28, 2016 | 05:41 EDT
Barclays analyst Douglas Tsao downgraded Alcobra to Underweight saying the FDA hold on the company's ongoing Phase 3 trial in adult attention-deficit/hyperactivity disorder likely delays readout of the program until mid-2018. The analyst views the hold as a surprise and cut his price target for the shares to $2 from $3.
News For ADHD From the Last 2 Days
There are no results for your query ADHD
